川芎嗪注射液联合酚妥拉明治疗慢性肺源性心脏病心力衰竭的临床研究

目的探讨川芎嗪注射液联合酚妥拉明治疗慢性肺源性心脏病心力衰竭的疗效。方法将100例慢性肺源性心脏病心力衰竭患者按抽签方法随机分为对照组和观察组，各50例。两组患者均给予基础治疗，观察组在上述治疗的基础上再给予川芎嗪注射液联合酚妥拉明加以治疗。比较两组疗效。结果观察组总有效率为96．O％，明显高于对照组的76．0％（X^2=4．298，P〈0．05）；观察组心功能分级出现明显改善，其中I级心功能患者显著性提高，与对照组差异有统计学意义（X^2=12．119，P〈0．01）；根据St．George’s呼吸问卷（SGRQ）评分标准，治疗后两组患者SGQR得分差异有统计学意义（t=4．899、5．727，P〈0．05或P〈0．01）。结论川芎嗪注射液联合酚妥拉明治疗慢性肺源性心脏病心力衰竭疗效尤佳，能够明显改善患者的心功能级别以及改善患者的生活质量，应在临床上加以推广与应用。

Clinical research of ligustrazine injection combined with phentolamine in the treatment of chronic pulmonary heart disease patients with heart failure

Objective To investigate the efficacy of ligustrazine injection combined with phentolamine in the treatment of chronic pulmonary heart disease patients with heart failure. Methods 100 chronic pulmonary heart dis- ease patients with heart failure were randomly divided into the control group and observation group, each group had 50 cases. The observation group was given ligustrazine injection combined with phentolamine on the basis of the conven- tional treatment. And the treatment efficacy of the two groups was compared. Results The total effective rate of the observation group was 96.0% ,which was significantly higher than 76.0% of the control group （X^2 = 4. 298, P 〈 0. 05）. The cardiac function classification of the observation group was improved significantly, and compared with the control group, the cardiac function in patients with grade I significantly improved（ X2 = 12.119, P 〈 0.05 ）. Accord- ing to St. George＇s Respiratory Questionnaire （SGRQ） standard, after treatment, SGQR score between the two groups had statistically significant difference （ t = 4. 899,5. 727, all P 〈 0.05 ）. Conclusion Ligustrazine injection combined with phentolamine has good efficacy in the treatment of chronic pulmonary heart disease, which can significantly improve the functional level of the patients＇ heart, and improve the patients＇ quality of life, and it should be promoted in clinical practice.